Analysts at Roth Capital upped their target price on shares of Ligand Pharmaceuticals (NASDAQ:LGND) from $51.00 to $65.00 in a research report issued to clients and investors on Wednesday, Analyst Ratings Network reports. The firm currently has a “buy” rating on the stock. Roth Capital’s price objective would suggest a potential upside of 35.67% from the stock’s previous close.
Shares of Ligand Pharmaceuticals (NASDAQ: LGND) opened at 47.91 on Wednesday. Ligand Pharmaceuticals has a one year low of $14.75 and a one year high of $50.85. The stock’s 50-day moving average is currently $38.44. The company’s market cap is $969.4 million.
Ligand Pharmaceuticals (NASDAQ:LGND) last issued its quarterly earnings data on Wednesday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.07. The company had revenue of $11.70 million for the quarter, compared to the consensus estimate of $10.00 million. On average, analysts predict that Ligand Pharmaceuticals will post $0.54 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on LGND. Analysts at Cantor Fitzgerald raised their price target on shares of Ligand Pharmaceuticals from $28.00 to $36.00 in a research note to investors on Monday, July 1st. Separately, analysts at Brean Capital raised their price target on shares of Ligand Pharmaceuticals from $25.00 to $45.00 in a research note to investors on Tuesday, June 25th. They now have a “buy” rating on the stock. Finally, analysts at Craig Hallum initiated coverage on shares of Ligand Pharmaceuticals in a research note to investors on Thursday, June 20th. They set a “buy” rating and a $60.00 price target on the stock.
One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $51.50.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biotechnology company that operates with a business model focused on developing or acquiring assets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.